Chapter Nine Venous Disease Coalition New Therapies for VTE VTE Toolkit.

Slides:



Advertisements
Similar presentations
Controversies in the management of Pulmonary Embolism
Advertisements

Rocky Mountain ACP Internal Medicine Conference November 22, 2012 Brian Wirzba, MD, FRCPC, FACP.
1 Novel Oral Anticoagulants: Benefits and risks Matthew Moles, MD December 4, 2012 University of Colorado.
Suresh Vedantham, M.D. Interventional Radiologist Associate Professor of Radiology & Surgery Washington University School of Medicine Vice-Chair, Venous.
Chapter Six Venous Disease Coalition Acute Management of VTE VTE Toolkit.
Results: 1.Progression of thrombus length and volume (40% vs. 28%; P
Long-Term Outcome After Additional Catheter-Directed Thrombolysis versus Standard Treatment for Acute Iliofemoral Deep Vein Thrombosis (The CaVenT Study):
Chapter Eleven Venous Disease Coalition Chronic Venous Insufficiency VTE Toolkit.
Joint Hospital Surgical Grand Round
Submassive Pulmonary Emboli: New Therapeutic Strategies
Pulmonary Embolism Dr Felix Woodhead Consultant Respiratory Physician.
Chapter Two Venous Disease Coalition Pathogenesis and Consequences of VTE VTE Toolkit.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient
Pulmonary Embolism Jeannette Corona. Title: Alteplase Treatment of Acute Pulmonary Embolism in the Intensive Care Unit Authors: Pamela L. Smithburger,
Pulmonary Embolism and Infarction
7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.
ANTICOAGULATION THERAPY OR CATHETER DIRECTED THROMBOLYSIS Alice Marinho, Carlos Veterano, Maricruz Nunes, Patrícia Baptista, Pedro Aguiar, Pedro Campelo,
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Moderate Pulmonary Embolism Treated with Thrombolysis (MOPETT) Trial Mohsen Sharifi, Curt Bay, Laura Skrocki, Farnoosh Rahimi, Mahshid Mehdipour A.T.Still.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva,
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.
Interesting Case Presentation March 1, 2012 Franklin C. Margaron, MD.
Presented by: Passant Mounir Nagy Under the supervision of: Prof. Dr/ Seham Hafez.
Case Presentation 45f acute CP, dyspnea, near-syncope Pale, diaphoretic, looks unwell Afebrile, HR 110, RR 32, BP 118/68 Sats 75% RA, 92% on NRB JVP elevated.
Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?
Jomo Osborne Lung-2015 Baltimore, USA July , 2015.
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,
Acute Venous Pulmonary Embolism Restore cardiopulmonary hemodynamics Avoid recurrence Avoid chronic thromboembolic pulmonary hypertension Restore cardiopulmonary.
Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.
Diagnosis and management of pulmonary thromboembolism DR.VIVEKANANTHAN D.A.,FRCA.,EDIC.,FFICM.,
Suresh Vedantham, M.D. Professor of Radiology & Surgery Mallinckrodt Institute of Radiology Washington University in St. Louis Interventional Management.
Ambulatory Venous Hypertension Components Obstruction Valve incompetence Obstruction Valve incompetence Obstruction and valve incompetence …Highest venous.
Dr Al Green MD FRCP Acute Physician JPUH
Case 2: IVC Filters 44 y/o male “preaching pastor” 10/23Generalized seizure Large AVM 2/12Embolization, left frontal craniotomy and resection c/b right.
PULMONARY EMBOLISM BY Dr. Hayam Hebah Associate professor of internal medicine AL-Maarefa College.
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Pulmonary Embolism and the Role of Echocardiograms in Management
Anticoagulation By: Charita Marthone, PharmD Candidate 4 th Year PharmD Candidate Fall Seminar Disease State Presentation Professor: Dr. Charlie Colquitt,
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Outpatient DVT assessment & treatment Daniel Gilada.
TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Catheter-Based Treatment of DVT: Who & When?
Current Standards for Treatment of DVT
Treatment of VTE Guidelines
Recent Updates and Debates in PE Care
By: Dr. Nalaka Gunawansa
Innovative DVT Therapy in 2016: Merely the End of the Beginning
Heart Valve Thrombosis & Neuro-Outcomes
Aspiration with Thrombolysis for Massive Pulmonary Embolism
Fibrinolysis in intermediate risk PE
Piotr Sobieszczyk M.D. Cardiovascular Division
Venous Thromboembolism
Thank you for viewing this presentation.
Long-Term Treatment of VTE: Case Studies
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
A Better Solution For Cancer Patients With VTE?
Interventional Management of DVT
Moderate/intermediate risk
Thrombolysis therapy for Pulmonary Embolism
Long-Term Treatment of VTE: Case Studies
Managing Pulmonary Embolism Posthospital Discharge
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Improving Management of Acute HTN in Patients With Stroke
Presentation transcript:

Chapter Nine Venous Disease Coalition New Therapies for VTE VTE Toolkit

Iliofemoral DVT VTE Toolkit Iliofemoral DVT has more serious long-term consequences than infra-inguinal DVT After 5 years: - 95% develop chronic venous insufficiency - nearly ½ have venous claudication - 15% develop venous ulcers - substantially reduced Quality of Life

Iliofemoral DVT VTE Toolkit Potential Benefits of Clot Removal: More rapid relief of obstruction Preservation of valve function Reduction in clot recurrence Reduction in post-thrombotic morbidity

Iliofemoral DVT VTE Toolkit Catheter-Directed Thrombus Reduction: Successful thrombolysis  - more rapid return to function - reduced chronic post-thrombotic symptoms - improved quality of life Bleeding  - Major bleeding <5% - Intracranial bleeding <1% Clinical pulmonary embolism <1%

Catheter-Directed Thrombolysis in Acute DVT (ATTRACT) VTE Toolkit Symptomatic iliofemoral DVT R Standard therapy: LMWH or IV heparin overlapping with warfarin Standard therapy + pharmaco- mechanical CDT: 1. Trellis-8 2. AngioJet Rheolytic system 3. Intra-thrombus rt-PA infusion Follow-up x 24 mos. N= centers NIH-funded S. Vedantham Primary efficacy outcome: incidence of PTS at 24 mos (Villalta scale) Secondary efficacy outcomes: severity of PTS; QOL (disease-specific and general); symptoms; valvular reflux & residual thrombus (at 1 year); cost- effectiveness; predictors of response Safety outcomes: major bleeding, symptomatic PE, rec VTE, death

Thrombolysis in Acute PE (PEITHO) VTE Toolkit Submassive PE* R Standard therapy: IV heparin > 48 h  LMWH overlapping with warfarin Standard therapy + IV bolus tenecteplase Follow-up x 1 mo. N~1, G. Meyer Primary outcome: composite of all-cause mortality + hemodynamic collapse (CPR, sBP 15 min) within 7 days Secondary outcomes: death, hemodynamic collapse, recurrent symptomatic PE, stroke, major bleeding within 7days; death <30 days Sponsors: Assistance Publique – Hopitaux de Paris, German Ministry of Education & Research, Boehringer-Ingelheim *RV dysfunction on echo or CTPA + elev troponin but normal BP

Venous Disease Coalition VTE Toolkit